A phase 3 trial shows that adding voclosporin to mycophenolate mofetil and low-dose glucocorticoids leads to higher rates of complete renal response and faster reduction in proteinuria for patients with...
Post hoc analyses of the phase 2 NOBILITY trial reveal that adding obinutuzumab to standard lupus nephritis therapy enhances kidney preservation and reduces glucocorticoid reliance.
In order to evaluate changes in trends of development of end-stage renal disease (ESRD) and mortality rates among patients with LN over the last 40 years, researchers conducted an observational...
In a recent study, researchers investigated the safety and efficacy of adding belimumab to a treatment regimen of rituximab and cyclophosphamide in patients with refractory lupus nephritis.
In a recent study, researchers sought to identify factors associated with rapid progression to end stage kidney disease (ESKD) in patients with lupus nephritis.
James Matera, DO, writes about a recent study that investigated the optimal duration of maintenance immunosuppressive therapy for patients with lupus nephritis, as well as asks if you typically perform...
The authors compared baseline characteristics of persons with juvenile-onset systemic lupus erythematosus (SLE) with and without lupus nephritis to identify clinical and laboratory predictors of lupus...
